- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Incorporating Real-World Evidence for HER2+ NSCLC
Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.
Video Player is loading.
EP: 1.Introduction and Current Landscape of HER2 in NSCLC
EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC
EP: 3.Treatment Considerations for Patients With HER2+ NSCLC
EP: 4.Latest Advances and Therapies for HER2+ NSCLC
EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC
EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC
EP: 7.HER2- Mutation Testing Considerations and Timing
EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC
Now Viewing
EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC
EP: 10.Key Takeaways on the Future of HER2 in NSCLC
EP: 11.Real-World Outcomes in HER2-Positive NSCLC
EP: 12.Managing Treatment Challenges in HER2-Directed Therapies
EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments
EP: 14.Patient Selection and Personalized Treatment Strategies
EP: 15.Navigating Healthcare Access and Decision-Making
Video content above is prompted by the following:
- What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
- (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Related Videos
No Significant Differences Found in Breast Cancer Treatment Between MA, FFS Beneficiaries: Galen Shearn-Nance, BS
Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
The Metro Nashville Public Schools Initiative
Recurrence Rates in Uncomplicated UTIs
Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
Adoption Strategies
Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
Mixed Outcomes Persist Between MA, FFS Beneficiaries: Johnie Rose, MD, PhD
Experts Push to Preserve Telehealth, Payment Parity Post Pandemic
Limited Clinical Insight Poses Barrier to Optimal NHL Treatment: Andrew Evens, DO
Related Content
Inflammatory Diets Raise Risk of Brain Disorders
April 10th 2025Article
Vegetables, fish oil, fruit, and high-fiber foods have anti-inflammatory effects, while low-fiber bread and animal fats are associated with pro-inflammatory effects. Diets heavier on these pro-inflammatory foods may be associated with higher risks of brain disorders.
Read More
